Baltimore, MD, June 1, 2016 – Living Pharma, Inc. announced today that it has added Isai Peimer, PhD, to its advisory board. Dr. Peimer is the former Managing Director of MedImmune Ventures, Inc., AstraZeneca’s investment fund, where he served from 2010 to 2016. Previously, he worked as a venture capitalist at Visium Asset Management, and as an Investment banker at J.P. Morgan and a Specialty Pharmaceuticals analyst at Alliance Bernstein. Dr. Peimer he began his career as a scientist at Merck.
Dr. Peimer has served as board member of Adheron Therapeutics (Acquired by Roche), Ambit Biosciences (NASDAQ: AMBI, acquired by Daiichi Sankyo), Armaron Bio Ltd., Corridor Pharmaceuticals (acquired by Astrazeneca), Inotek Pharmaceuticals (NASDAQ: ITEK), Xencor (NASDAQ: XNCR) and The Ivy Foundation Biomedical Innovation Review Board at University of Virginia.
Dr. Peimer is a graduate of Emory University; B.A. in Chemistry summa cum laude, and earned his M.B.A. from the Tuck School of Business at Dartmouth.
“We are pleased that Dr. Peimer has agreed to serve on Living Pharma’s advisory board. His experience will prove invaluable in our fundraising efforts, and in the execution of our commercial strategy. We look forward to working with Dr. Peimer to build a world class company focused on developing cures for patients suffering from hematologic and solid organ cancers.” said Mr. Ronald Dudek, founder and president of Living Pharma.
About Living Pharma
Living Pharma develops Personalized CAR T Cell Therapy™. We are focused on developing therapeutic immuno-oncology products optimized for each individual patient. Our universal Anti-Tag Chimeric Antigen Receptor (AT-CAR™) T cells can be tailored to the individual patient’s cancer and disease phenotype. The company is headquartered in Baltimore, MD. For more information, visit http://www.livingpharma.com.